Morgan Stanley trims Ventyx (NASDAQ: VTYX) holdings to 0.3% stake

Rhea-AI Filing Summary

Morgan Stanley has significantly reduced its stake in Ventyx Biosciences, Inc. The firm now reports beneficial ownership of 237,358 shares of Ventyx common stock, representing about 0.3% of the outstanding class. Morgan Stanley states it has ceased to be the beneficial owner of more than five percent of these securities and holds the position in the ordinary course of business, without any purpose of changing or influencing control of the company.

Insights

Equity ownership and disclosure analyst

Morgan Stanley discloses a reduced, sub‑5% position in Ventyx.

Morgan Stanley now reports beneficial ownership of 237,358 Ventyx Biosciences common shares, or 0.3% of the class. The filing notes that, as of this amendment, it is no longer a beneficial owner of more than five percent of the stock.

The position is described as being acquired and held in the ordinary course of business, with no intention of changing or influencing control of Ventyx Biosciences. Voting and dispositive power over all reported shares is shared rather than sole, which is typical for large financial institutions managing client and affiliate accounts.

The filing also clarifies that it only reflects securities attributed to certain Morgan Stanley operating units, excluding other disaggregated units. Overall, this represents an updated ownership disclosure rather than a strategic corporate action, so its impact on the broader business outlook is limited.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Ventyx Biosciences, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

92332V107

(CUSIP Number)

01/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 92332V107

1

Names of Reporting Persons

Morgan Stanley

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 237,358.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 237,358.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

237,358.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.3 %

12

Type of Reporting Person (See Instructions)

HC, CO

Comment for Type of Reporting Person: As of the date hereof, Morgan Stanley has ceased to be the beneficial owner of more than five percent of the class of securities.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Ventyx Biosciences, Inc.
(b)	Address of issuer's principal executive offices: 12790 EL CAMINO REAL, SUITE 200, SAN DIEGO, CA, 92130
Item 2.
(a)	Name of person filing: Morgan Stanley
(b)	Address or principal business office or, if none, residence: 1585 Broadway, New York, NY 10036
(c)	Citizenship: Delaware
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 92332V107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s).
(b)	Percent of class: 0.3 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s).
	(ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s).
	(iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s).
	(iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Morgan Stanley

Signature:	Christopher O'Hara
Name/Title:	Authorized Signatory, Morgan Stanley
Date:	02/06/2026

FAQ

How many Ventyx Biosciences (VTYX) shares does Morgan Stanley currently report owning?

Morgan Stanley reports beneficial ownership of 237,358 shares of Ventyx Biosciences common stock. This holding is reported with shared voting and shared dispositive power, reflecting positions managed across certain Morgan Stanley operating units rather than a single proprietary stake.

What percentage of Ventyx Biosciences (VTYX) does Morgan Stanley’s position represent?

Morgan Stanley’s reported position represents about 0.3% of Ventyx Biosciences’ common stock. This updated percentage shows that Morgan Stanley is now a relatively small holder, well below the five percent threshold that typically triggers more prominent ownership reporting.

What does the Schedule 13G/A say about Morgan Stanley’s ownership falling below 5% of Ventyx (VTYX)?

The filing states that Morgan Stanley has ceased to be the beneficial owner of more than five percent of Ventyx’s common stock. This confirms a reduction from a previously higher level of ownership to a smaller, sub‑5% position in the company’s equity.

Is Morgan Stanley’s Ventyx (VTYX) stake intended to influence control of the company?

Morgan Stanley certifies the securities were acquired and are held in the ordinary course of business. It also states they were not acquired and are not held for the purpose of changing or influencing control of Ventyx, nor in connection with any such control‑related transaction.

Who signed the Morgan Stanley Schedule 13G/A related to Ventyx Biosciences (VTYX)?

The Schedule 13G/A was signed by Christopher O’Hara as an Authorized Signatory for Morgan Stanley. The signature section also includes a certification that, after reasonable inquiry, the information provided about the Ventyx ownership position is true, complete, and correct.

What type of reporting person is Morgan Stanley in the Ventyx (VTYX) Schedule 13G/A?

Morgan Stanley is identified as an HC, or parent holding company or control person. The filing explains it aggregates securities beneficially owned by certain Morgan Stanley operating units, while excluding other units that report their holdings on a disaggregated basis under SEC guidance.